The impact of thyroid hormones on patients with hepatocellular carcinoma

Matthias Pinter¹,², Lukas Haupt¹, Florian Hucke¹,²,³, Simona Bota¹,²,³, Theresa Bucsics¹,², Michael Trauner¹, Markus Peck-Radosavljevic¹,²,³, Wolfgang Sieghart¹,²

¹ Division of Gastroenterology & Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria, 2 Liver Cancer (HCC) Study Group Vienna, Vienna, Austria, 3 Department of Gastroenterology & Hepatology, Endocrinology and Nephrology, Klinikum Klagenfurt am Wörthersee, Klagenfurt, Austria

* wolfgang.sieghart@meduniwien.ac.at

Abstract

Background & aims

Hypothyroidism has recently been proposed as predisposing factor for HCC development. However, the role of thyroid hormones (TH) in established HCC is largely unclear. We investigated the impact of TH on clinical characteristics and prognosis of HCC patients.

Methods

Of 838 patients diagnosed with nonsurgical HCC at the Division of Gastroenterology and Hepatology/Medical University of Vienna between 1992 and 2012, 667 patients fulfilled the inclusion criteria. The associations of thyroid function tests with patient, liver, and tumor characteristics as well as their impact on overall survival (OS) were investigated.

Results

Thyroid hormone substitution was more often observed in patients with low thyroid-stimulating hormone (TSH) concentration and in patients with elevated free tetraiodothyronine (fT4). Patients with high TSH (>3.77uU/ml) concentrations had larger tumors, while the opposite was true for patients with low TSH (<0.44uU/ml) concentrations. Subjects with elevated fT4 (>1.66ng/dl) were more likely to have elevated CRP. While TSH was only associated with OS in univariate analysis (≤1.7 vs. >1.7uU/ml, median OS (95%CI), 12.3 (8.9–15.7 months) vs. 7.3 months (5.4–9.2 months); p = 0.003), fT4 (≤1.66 vs. >1.66ng/dl, median OS (95% CI), 10.6 (7.5–13.6 months) vs. 3.3 months (2.2–4.3 months); p = 0.007) remained an independent prognostic factor for OS (HR (95%CI) for fT4>1.66ng/dl, 2.1 (1.3–3.3); p = 0.002) in multivariate analysis.

Conclusions

TSH and fT4 were associated with prognostic factors of HCC (i.e., tumor size, CRP level). Elevated fT4 concentrations were independently associated with poor prognosis in HCC. Further studies are needed to characterize the role of TH in HCC in detail.
Introduction

Components of thyroid hormone signaling are implicated in the development and progression, as well as in the prevention of various cancers including hepatocellular carcinoma (HCC) [1–3]. HCC usually develops in patients with liver cirrhosis [4, 5] and represents the second most common cause of cancer-related mortality in men globally [6].

The thyroid hormones (TH) tetraiodothyronine (T4) and, to a lesser extent, triiodothyronine (T3) are produced in the thyroid gland in a complex multi-step process, which is tightly controlled by the hypothalamus-pituitary-thyroid axis. Hypothalamic neurons produce the tripeptide thyrotropin-releasing-hormone (TRH), which uses the pituitary portal venous system to reach the anterior pituitary gland, where it binds to the TRH receptor in thyrotropic cells, and thereby stimulates both the production and pulsatile release of the glycoprotein thyrotropin (thyroid-stimulating hormone, TSH). By binding to the TSH-receptor situated at the basolateral membrane of thyrocytes, TSH activates thyroid hormone production and secretion.

The vast majority of both thyroid hormones is bound to the plasma proteins and therefore unable to bind to receptors in target tissues. This constellation allows preparation of a large pool of hormones, which can quickly be released when needed. Conversely, the smaller, unbound fraction of thyroid hormones is responsible for the actual physiological effects. The thyroid gland predominantly secretes T4, most of which is subjected to peripheral metabolism by deiodinase enzymes [7].

Since TH display extensive influence on regulatory mechanisms affecting the control of cellular growth and metabolism [7–10], there are myriad possible modes of interaction with both the development and progression of HCC. Although hypothyroidism has been shown to be associated with an elevated risk of HCC development [2, 11, 12], the role of TH in established HCC remains to be elucidated. Several preclinical studies have linked TH signaling to tumor-promoting actions, especially at advanced stages of hepatocarcinogenesis [13–15]. However, little is known about both the prevalence and clinical role of TH in patients with manifest HCC. Hence, we aimed to investigate the association of TH with clinical patient and tumor characteristics as well as their impact on the prognosis of HCC patients.

Materials and methods

Patient selection

Data from all patients who were diagnosed with HCC by biopsy or radiological imaging according to the European Association for the Study of the Liver (EASL) [16] diagnostic criteria between August 1992 and February 2013 at the Medical University of Vienna were retrospectively collected and incorporated into a database. Patients who had received surgical treatment for HCC at any time after diagnosis were excluded from analysis. Only patients aged ≥18 years with TSH levels available at the time of diagnosis were eligible. Collection and retrospective analysis was approved by the Ethics Committee of the Medical University of Vienna.

Data acquisition

The date of HCC diagnosis (date of biopsy if available or diagnostic imaging) was considered the baseline of this study. Patient information was collected in a preexisting MS Access 2010 database (HCC database) in a pseudo-anonymous manner. Patient characteristics, laboratory parameters including thyroidal function (TSH, T3, T4, fT3, fT4), tumor characteristics, and parameters representing liver function were recorded from the patients’ charts and from the electronic patients’ information system. Determination of thyroid status was based on TSH and fT4 levels. We formed 5 subgroups: euthyreosis, hyperthyreosis (primary, secondary, and...
euthyroid hyperthyroxinemia), subclinical hyperthyreosis, subclinical hypothyreosis, hypothyreosis (primary and secondary), and thyroid hormone substitution. Liver function was assessed by MELD score and Child-Pugh score. The latter has been incorporated in the Barcelona Clinic Liver Cancer classification, the most widely used staging system for HCC, which has been endorsed by the American and European HCC guidelines [16, 17].

Statistics
Baseline characteristics were summarized using descriptive statistics. Chi square test or Fisher’s exact test were used to compare nominal data. Overall survival (OS) was defined as the time from date of diagnosis (date of biopsy if available or diagnostic imaging) until date of death or last contact. Survival curves were calculated using the Kaplan-Meier method and were compared by means of the log rank test (univariate analysis). Variables that reached a p-value of <0.05 in univariate analysis were entered into a multivariate analysis. The multivariate analysis was performed using a Cox proportional hazard regression model. Statistical tests were two-sided and a p-value <0.05 was considered significant. All statistical analyses were performed using SPSS version 17.0 (SPSS Inc., Chicago, IL).

Results
Patient characteristics
Of 667 patients included (Fig 1), 82% of the patients were male, with a male to female ratio of 4.6:1. The median age at diagnosis was 64 years (range, 32–87 years). Six percent of all patients were on thyroid hormone substitution. Detailed patient characteristics are shown in Table 1. Additional information on thyroid function is given in S1 Table. Mean follow-up was 65.5 months. Five hundred and forty-four (82%) patients died during the observation period.

Association of thyroid-stimulating hormone (TSH) and free tetraiodothyronine (fT$_4$) with patient, liver, and tumor characteristics
TSH abnormalities significantly differed between age groups. While patients with low TSH concentrations were generally older (age >65 vs. ≤65 years, 68 vs. 32%) those with high TSH (>3.77uU/ml) levels were predominantly younger (age >65 vs. ≤65 years, 39 vs. 61%; p = 0.007). Thyroid hormone substitution was more often observed in patients with low TSH (<0.44uU/ml) concentration (24%) compared to those with normal (4%) or elevated TSH (13%) levels (p<0.001). Finally, patients with high TSH concentrations had larger tumors (tumor >5cm vs. ≤5cm, 61 vs. 39%) while the opposite was true for patients with low TSH concentrations (tumor >5cm vs. ≤5cm, 32 vs. 68%; p = 0.005). No association was observed between other variables including e.g. Child-Pugh stage, metastasis, or macrovascular invasion (Table 2). Notably, in patients with larger HCC (>5cm), TSH levels were only significantly associated with sex and thyroid hormone substitution, but not with other variables that might correlate with larger HCC (i.e., etiology, Child-Pugh stage) (S2 Table).

Free T$_4$ (fT$_4$) levels were available in 313 patients. Since sample size of hypothyroid patients (fT$_4$ levels below 0.76ng/dl) was too small (n = 4) to allow for robust analysis, fT$_4$ levels were divided into two groups (≤1.66 and >1.66ng/dl, hereafter referred to as ‘normal’ and ‘elevated’, respectively). The proportion of female patients was higher in patients with elevated fT$_4$ levels (normal vs. elevated fT$_4$, 16 vs. 36%; p = 0.025). Thyroid hormone substitution was more frequently observed in patients with elevated fT$_4$ levels (normal vs. elevated fT$_4$, 6 vs. 32%; p<0.001). Finally, subjects with elevated fT$_4$ were more likely to have elevated CRP levels (normal vs.
No association was observed between other variables representing liver function and tumor burden, respectively (S3 Table).

Since information on $T_3$, $T_4$, and $fT_3$ was missing in 82–97% of patients due to the retrospective character of this analysis (S1 Table), we could not assess their association with patient, liver, and tumor characteristics.

Uni- and multivariate analyses of prognostic factors

Median survival of the study population ($n = 667$) was 9.3 months (95% CI, 7.6–11.0 months).
Table 1. Patient characteristics.

|                                | N = 667 | 100% |
|--------------------------------|---------|------|
| **Age (years)**                | Mean±SD | 64±9.6 |
| Range                          |         | 32–87 |
| **Sex**                        | Male    | 547  | 82  |
|                                | Female  | 120  | 18  |
| **Diabetes**                   | NIDDM   | 152  | 23  |
|                                | IDDM    | 78   | 12  |
|                                | None    | 437  | 66  |
| **BMI (kg/m^2)**               | Mean±SD | 27±4.8 |
| **Etiology**                   | Alcohol | 304  | 46  |
|                                | HCV     | 194  | 29  |
|                                | HBV     | 52   | 8   |
|                                | NASH    | 20   | 3   |
|                                | Cryptogenic | 65   | 10  |
|                                | other   | 32   | 5   |
| **Child-Pugh**                 | A       | 286  | 43  |
|                                | B       | 219  | 33  |
|                                | C       | 162  | 24  |
| **MELD**                       | Mean±SD | 13±5.7 |
| **ECOG PS**                    | 0       | 328  | 49  |
|                                | >1      | 339  | 51  |
| **Largest tumor**              | ≤5cm    | 313  | 47  |
|                                | >5cm    | 354  | 53  |
| **Macrovascular Invasion**     | No      | 489  | 73  |
|                                | Yes     | 178  | 27  |
| **Extrahepatic metastases**    | BCLC stage |       |     |
|                                | No      | 577  | 87  |
|                                | Yes     | 90   | 14  |
|                                | A       | 90   | 14  |
|                                | B       | 143  | 21  |
|                                | C       | 268  | 40  |
|                                | D       | 166  | 25  |
| **First line therapy**         | PEI/RFA | 138  | 21  |
|                                | TACE    | 180  | 27  |
|                                | Sorafenib | 63   | 9   |
|                                | BSC     | 152  | 23  |
|                                | Other   | 134  | 20  |
| **CRP (mg/dl)**                | Mean±SD | 2.62±3.59 |
| **AFP (IU/ml)**                | Mean±SD | 5982±25114 |
| **TSH (uU/ml)**                | Mean±SD | 2.2±2.3  |
| **fT4 (ng/dl)**                | Mean±SD | 1.3±0.3  |
| **Thyroid hormone substitution** | Yes | 41 | 6 |
|                                | No     | 626  | 94  |

Abbreviations: AFP, α-fetoprotein; BCLC, Barcelona-Clinic Liver Cancer; BMI, body mass index; BSC, best supportive care; CRP, C-reactive protein; ECOG PS, Eastern Cooperative Oncology Group performance status; fT4, free tetraiodothyronine; HBV, hepatitis B virus; HCV, hepatitis C virus; MELD, model of end-stage liver disease; NASH, non-alcoholic steatohepatitis; (N)IDDM, (non) insulin dependent diabetes mellitus; PEI, percutaneous ethanol injection; RFA, radiofrequency ablation; TACE, transarterial chemoembolization; TSH, thyroid-stimulating hormone.

1 missing, n = 23;
2 missing, n = 36;
3 missing, n = 9;
4 missing, n = 354
In univariate analysis (Table 3), both, TSH (TSH \leq 1.7 vs. >1.7uU/ml, median OS (95%CI), 12.3 (8.9–15.7 months) vs. 7.3 months (5.4–9.2 months); p = 0.003; Fig 2A) and fT4 (fT4 \leq 1.66 vs. >1.66ng/dl, median OS (95%CI), 10.6 (7.5–13.6 months) vs. 3.3 months (2.2–4.3 months); p = 0.007; Fig 2B) were associated with OS. Patients with manifest hyperthyroid status (n = 17) had worse survival compared to those with normal fT4 levels (i.e., euthyreosis, subclinical

### Table 2. Association between thyroid-stimulating hormone (TSH) and patient, liver, and tumor characteristics (n = 667).

|                          | TSH, N (%)                  | N     | low (%) | normal (%) | high (%) | p-value |
|--------------------------|------------------------------|-------|---------|------------|----------|---------|
| **Sex**                  |                              |       |         |            |          |         |
| Male                     | 547                          | 36 (72)| 458 (84)| 53 (77)    |          |         |
| Female                   | 120                          | 14 (28)| 90 (16) | 16 (23)    |          | 0.062   |
| **Age**                  |                              |       |         |            |          |         |
| \( \leq 65 \)            | 339                          | 16 (32)| 281 (51)| 42 (61)    |          |         |
| >65                      | 328                          | 34 (68)| 267 (49)| 27 (39)    |          | 0.007   |
| **Diabetes**             |                              |       |         |            |          |         |
| NIDDM                    | 152                          | 9 (18) | 124 (23)| 19 (28)    |          |         |
| IDDM                     | 78                           | 4 (8)  | 69 (13) | 5 (7)      |          |         |
| None                     | 437                          | 37 (74)| 355 (65)| 45 (65)    |          | 0.418   |
| **BMI (kg/m^2)\(^1\)**  |                              |       |         |            |          |         |
| <18.5                    | 6                            | 1 (2)  | 5 (1)   | 0 (0)      |          |         |
| 18.5–25                  | 229                          | 20 (40)| 189 (36)| 20 (29)    |          |         |
| >25                      | 409                          | 29 (58)| 332 (63)| 48 (71)    |          | 0.470   |
| **Etiology**             |                              |       |         |            |          |         |
| Alcohol                  | 304                          | 25 (50)| 254 (46)| 25 (36)    |          |         |
| HCV                      | 194                          | 10 (20)| 156 (29)| 28 (41)    |          |         |
| HBV                      | 52                           | 4 (8)  | 46 (8)  | 2 (3)      |          |         |
| NASH                     | 20                           | 0 (0)  | 19 (4)  | 1 (1)      |          |         |
| Other                    | 97                           | 11 (22)| 73 (13) | 13 (19)    |          | 0.083   |
| **Thyroid hormone substitution** |                      | 41 | 12 (24) | 20 (4)    | 9 (13) | <0.001 |
| Yes                      | 626                          | 38 (76)| 528 (96)| 60 (87)    |          |         |
| No                       |                              |       |         |            |          |         |
| **Child-Pugh**           |                              |       |         |            |          |         |
| A                        | 286                          | 21 (42)| 244 (45)| 21 (30)    |          |         |
| B                        | 219                          | 15 (30)| 178 (33)| 26 (38)    |          |         |
| C                        | 162                          | 14 (28)| 126 (23)| 22 (32)    |          | 0.216   |
| **MELD**                 |                              |       |         |            |          |         |
| <12                      | 361                          | 27 (54)| 302 (55)| 32 (46)    |          |         |
| \( >12 \)                | 306                          | 23 (46)| 246 (45)| 37 (54)    |          | 0.390   |
| **Largest tumor**        |                              |       |         |            |          |         |
| \( \leq 5cm \)           | 313                          | 34 (68)| 252 (46)| 27 (39)    |          |         |
| \( >5cm \)               | 354                          | 16 (32)| 296 (54)| 42 (61)    |          | 0.005   |
| **Macrovascular invasion**|                             |       |         |            |          |         |
| No                       | 489                          | 41 (82)| 403 (74)| 45 (65)    |          |         |
| Yes                      | 178                          | 9 (18) | 145 (27)| 24 (35)    |          | 0.119   |
| **Extrahepatic metastases**|                            |       |         |            |          |         |
| No                       | 577                          | 44 (88)| 470 (86)| 63 (91)    |          |         |
| Yes                      | 90                           | 6 (12) | 78 (14) | 6 (9)      |          | 0.425   |
| **CRP (mg/dl)\(^2\)**   |                              |       |         |            |          |         |
| <1                       | 285                          | 22 (48)| 239 (46)| 24 (36)    |          |         |
| \( \geq 1 \)             | 346                          | 24 (52)| 279 (54)| 43 (64)    |          | 0.260   |
| **AFP (IU/ml)\(^3\)**   |                              |       |         |            |          |         |
| \( \leq 100 \)           | 362                          | 23 (47)| 305 (57)| 34 (49)    |          |         |
| \( >100 \)               | 296                          | 26 (53)| 235 (44)| 35 (51)    |          | 0.262   |

**Abbreviations**: AFP, \( \alpha \)-fetoprotein; BMI, body mass index; CRP, C-reactive protein; HBV, hepatitis B virus; HCV, hepatitis C virus; MELD, model of end-stage liver disease; NASH, non-alcoholic steatohepatitis; (N)IDDM, (non) insulin dependent diabetes mellitus; TSH, thyroid-stimulating hormone.

**Definitions**: TSH low, <0.44uU/ml; TSH normal, 0.44–3.77uU/ml; TSH high, >3.77uU/ml

\(^1\) missing, n = 23;
\(^2\) missing, n = 36;
\(^3\) missing, n = 9

https://doi.org/10.1371/journal.pone.0181878.t002
hyperthyreosis. The cause of death in patients with hyperthyreosis was tumor progression in 6 patients, liver failure/decompensation in 4 subjects, and unknown in 7 patients. However, thyroid status was not significantly associated with OS, most likely due to small patient numbers in some subgroups.

Table 3. Univariate analysis of prognostic factors (N = 667).

|                | Overall survival (months) | P-value |
|----------------|---------------------------|---------|
|                | N  | Median | 95% CI |      |
| Age            |    |        |        |      |
| <65            | 339| 7.5    | 4.9–10.1 | 0.203 |
| >65            | 328| 10.5   | 8.1–12.9 | 0.326 |
| Etiology       |    |        |        |      |
| Viral          | 246| 10.5   | 7.7–13.3 |      |
| Others         | 421| 8.8    | 6.7–10.9 |      |
| Child-Pugh     |    |        |        |      |
| A              | 286| 16.2   | 13.8–18.7 | <0.001 |
| B              | 219| 7.9    | 5.1–10.8 |      |
| C              | 162| 2.4    | 1.9–2.9 |      |
| Largest tumor  |    |        |        |      |
| ≤5cm           | 313| 14.3   | 11.7–16.9 | <0.001 |
| >5cm           | 354| 6.1    | 5.0–7.2 |      |
| ECOG PS        |    |        |        |      |
| 0              | 328| 16.7   | 14.2–19.3 | <0.001 |
| >1             | 339| 4.0    | 3.3–4.8 |      |
| Macrovascular invasion |  |        |        |      |
| No             | 489| 12.6   | 10.7–14.5 | <0.001 |
| Yes            | 178| 3.7    | 2.4–5.0 |      |
| Extrahepatic spread |  |        |        |      |
| No             | 577| 11.3   | 9.3–13.4 | <0.001 |
| Yes            | 90 | 3.4    | 1.9–5.0 |      |
| First-line therapy |  |        |        |      |
| PEI/RFA        | 138| 20.9   | 16.6–25.2 |      |
| TACE           | 180| 15.5   | 13.3–17.7 |      |
| Sorafenib      | 63 | 8.1    | 4.0–12.2 |      |
| BSC            | 152| 1.9    | 1.4–2.4 |      |
| Other          | 134| 6.0    | 4.4–7.6 |      |
| AFP (IU/ml)    |    |        |        |      |
| <100           | 362| 14.0   | 11.8–16.2 | <0.001 |
| >100           | 296| 5.8    | 4.5–7.1 |      |
| CRP (mg/dl)    |    |        |        |      |
| <1             | 285| 17.9   | 14.8–20.9 | <0.001 |
| ≥1             | 346| 4.1    | 3.3–4.9 |      |
| TSH (uU/ml)    |    |        |        |      |
| ≤1.7           | 336| 12.3   | 8.9–15.7 |      |
| >1.7           | 331| 7.3    | 5.4–9.2 |      |
| fT<sub>4</sub> (ng/dl) |    |        |        |      |
| ≤1.66          | 288| 10.6   | 7.5–13.6 | 0.003 |
| >1.66          | 25 | 3.3    | 2.2–4.3 |      |
| Thyroid hormone substitution |  |        |        |      |
| Yes            | 41 | 11.9   | 4.0–19.7 |      |
| No             | 626| 9.0    | 7.2–10.7 | 0.474 |
| Thyroid status |    |        |        |      |
| Euthyreosis    | 200| 10.8   | 6.5–15.2 |      |
| Hyperthyreosis | 17 | 3.3    | 1.4–5.1 |      |
| Subclinical hyperthyreosis | 22 | 14.7 | 1.4–28.0 |      |
| Subclinical hypothyreosis | 47 | 6.1 | 0–13.5 |      |
| Hypothyreosis  | 3  | 0.7    | 0.2–1.2 |      |
| TH substitution | 41 | 11.9 | 4.0–19.7 | 0.195 |

**Abbreviations:** AFP, α-fetoprotein; BSC, best supportive care; CRP, C-reactive protein; ECOG PS, Eastern Cooperative Oncology Group performance status; fT<sub>4</sub>, free triiodothyronine; MELD, model of end-stage liver disease; PEI, percutaneous ethanol injection; RFA, radiofrequency ablation; TACE, transarterial chemoembolization; TH, thyroid hormone; TSH, thyroid-stimulating hormone.

1 missing, n = 9;
2 missing, n = 36;
3 missing, n = 354

[1] https://doi.org/10.1371/journal.pone.0181878.t003
Other variables that were significantly associated with OS included Child-Pugh class, tumor size, Eastern Cooperative Oncology Group (ECOG) performance status (PS), macrovascular invasion (MVI), extrahepatic metastases, first-line therapy, α-fetoprotein (AFP) level, and C-reactive protein (CRP) level. Importantly, thyroid hormone substitution had no impact on OS. Given that fT₄ levels were only available in 313 patients, we did not include both TSH and fT₄ in the same multivariate Cox regression model, but analyzed them separately with all other variables that were significantly associated with OS in univariate analysis. Finally, fT₄ (HR (95%CI) for fT₄ > 1.66 ng/dl, 2.1 (1.3–3.3); p = 0.002) remained an independent prognostic factor for OS (Table 4), while TSH was not significantly associated with OS in multivariate analysis (S4 Table).

After separating patients into early-intermediate (BCLC A-B) and advanced-terminal (BCLC C-D) stage, fT₄ remained associated with OS. Median survival in the early-intermediate stage group was 25.3 months (95%CI, 20.1–30.6 months) for fT₄ ≤ 1.66 (n = 97) and 15.5 months (95%CI, 9.2–21.8 months) for fT₄ > 1.66 (n = 8) (p = 0.043). Similarly, in the advanced-terminal stage group, patients with fT₄ ≤ 1.66 (n = 191) had a significantly (p = 0.038) longer survival of 4.5 months (95%CI, 3.1–5.8 months) compared to 2.8 months (95%CI, 1.5–4.1 months) in patients with fT₄ > 1.66 (n = 17).

Discussion

In our cohort, 10% of patients had elevated TSH levels similar to the prevalence of hypothyroidism in patients with HCC reported by Hassan et al. (HCC patients vs. controls, 11.7 vs. 8%) [12]. Hypothyroidism has profound effects on metabolism and has therefore been linked to various conditions which either directly constitute an HCC risk factor or have the ability to contribute to the development of known predisposing conditions for HCC, such as obesity [18–21], diabetes [22–25], non-alcoholic fatty liver disease (NAFLD) [20, 26, 27], and hepatitis C infection [12, 28, 29]. Interestingly, Tarantino and colleagues reported that BMI predicted the presence of spleno-renal shunts and spleno-renal shunts were associated with an increased HCC incidence [30].

However, in our study, high serum TSH concentration was neither associated with type II diabetes mellitus nor BMI. Although etiology of liver disease was not significantly associated
with TSH levels, HCV was more frequently observed in patients with high TSH levels (41%) compared to those with normal (29%) or low (20%) TSH. In contrast, Reddy and colleagues [31] found that hypothyroidism was more prevalent in patients with unknown etiology than in those with HCV or alcoholic liver disease. Additionally, we observed NASH only in patients with normal or elevated TSH but not in those with low TSH levels.

Notably, elevated TSH was associated with larger tumors in our study. In contrast, in breast cancer, hypothyroid patients were more likely to be diagnosed with a smaller tumor and at an earlier stage compared to euthyroid patients [32]. Moreover, in prostate cancer, serum T_3 was higher in more advanced clinical stage, even though none of the men had levels above the normal range [33].

In terms of survival, patients with higher TSH levels showed a significantly worse outcome in univariate analysis. However, this effect did not hold true upon multivariate analysis when adjusting for other prognostic factors including Child-Pugh class, tumor size, performance status, macrovascular invasion, extrahepatic spread, tumor treatment, AFP, and CRP levels.

Next, we investigated the prevalence of abnormal fT_4 levels, available in 313 of 667 patients. Elevated fT_4 was found in 25 patients (4% of all patients, n = 667; 8% of those whose fT_4 levels where available, n = 313). In comparison, a large study conducted in the United States reported a prevalence of only 0.5% for clinical hyperthyroidism. Notably, they used total instead of free T_4 concentrations but adjusted for the common T_4-confounders pregnancy and estrogen.

Table 4. Multivariate analysis of prognostic factors.

|                       | Overall survival | P-value (Cox regression) |
|-----------------------|------------------|--------------------------|
| **Child-Pugh**        |                  |                          |
| A                     | 1                |                          |
| B                     | 1.7              | 1.3–2.4                  | 0.001      |
| C                     | 2.3              | 1.5–3.6                  | <0.001     |
| **Largest tumor**     |                  |                          |
| ≤5cm                  | 1                |                          |
| >5cm                  | 1.4              | 1.1–1.8                  | 0.017      |
| **ECOG PS**           |                  |                          |
| 0                     | 1                |                          |
| ≥1                    | 1.3              | 0.9–1.8                  | 0.134      |
| **Macrovascular invasion** |      |                          |
| No                    | 1                |                          |
| Yes                   | 1.2              | 0.9–1.7                  | 0.285      |
| **Extrahepatic spread** |                |                          |
| No                    | 1                |                          |
| Yes                   | 1.7              | 1.1–2.5                  | 0.013      |
| **First-line therapy** |                |                          |
| PEI/RFA               | 1                |                          |
| TACE                  | 1.2              | 0.8–1.8                  | 0.315      |
| Sorafenib             | 1.4              | 0.6–2.9                  | 0.409      |
| BSC                   | 6.0              | 3.8–9.4                  | <0.001     |
| Other                 | 1.7              | 1.2–2.4                  | 0.004      |
| **AFP (IU/ml)**       |                  |                          |
| ≤100                  | 1                |                          |
| >100                  | 1.5              | 1.2–2.0                  | 0.003      |
| **CRP (mg/dl)**       |                  |                          |
| <1                    | 1                |                          |
| ≥1                    | 1.6              | 1.2–2.2                  | 0.003      |
| **fT_4 (ng/dl)**      |                  |                          |
| ≤1.66                 | 1                |                          |
| >1.66                 | 2.1              | 1.3–3.3                  | 0.002      |

**Abbreviations:** AFP, α-fetoprotein; BSC, best supportive care; CRP, C-reactive protein; ECOG PS, Eastern Cooperative Oncology Group performance status; fT_4, free tetraiodothyronine; PEI, percutaneous ethanol injection; RFA, radiofrequency ablation; TACE, transarterial chemoembolization.

https://doi.org/10.1371/journal.pone.0181878.t004
therapy [34]. In an epidemiologic study by Hassan et al., the prevalence of hyperthyroidism was 1.9% among HCC patients and 1.3% among controls [12].

In our cohort, elevated fT$_4$ concentrations were not associated with etiology of liver disease and variables representing liver function or tumor burden. However, patients with elevated fT$_4$ more frequently had elevated CRP levels which indicate worse prognosis in HCC and could be a reflection of the “inflammatory field effect” [35]. This effect could directly fuel tumor progression as CRP levels are an accepted surrogate marker for the release of Interleukin (IL) -6, an important regulator of CRP secretion, which in turn is associated with both acceleration of HCC development and metastasis [35–38]. Additionally, thyroid hormone replacement was more common in patients with increased fT$_4$ levels (fT$_4$$>$1.66, 6 vs. 32%).

We next investigated the impact of fT$_4$ on the prognosis of HCC patients and found that elevated fT$_4$ levels at the time of HCC diagnosis were significantly associated with poor OS. This effect held true even after adjusting for other known prognostic factors for HCC in a multivariate Cox regression model.

These results are supported by several preclinical studies showing that thyroid hormone signaling promotes tumor invasiveness and metastasis [2, 13, 15, 39, 40], and could be of clinical relevance mainly for two reasons. First, fT$_4$ is a valuable prognostic parameter in HCC that is widely available, non-invasively collectable, and objective. Second, considering both the association between thyroid hormone substitution and elevated fT$_4$ levels as well as the strong prognostic relevance of elevated fT$_4$, our data could suggest some caution when replacing thyroid hormones in patients with established HCC, as hormone replacement-induced fT$_4$ elevation might render tumors more aggressive. This should especially be considered in patients with advanced HCC receiving sorafenib therapy where hypothyroidism often occurs [41–43], and might prompt physicians to initiate hormone replacement therapy.

Notably, other studies reported that T$_3$ treatment led to regression of preneoplastic lesions in rodent models of heptocarcinogenesis [44, 45].

The main limitation of this study was the lack of patients with low fT$_4$ levels, which precluded the investigation of effects of overt hypothyroidism on HCC and only allowed analyzing the effect of hypothyroidism using TSH levels. This especially impeded the analysis of the impact of thyroid hormones on HCC with metabolic background. Furthermore, the small sample size of patients with abnormal fT$_4$ levels did not allow subgroup analyses within the BCLC stages and Child-Pugh class. As thyroid hormones may exert opposing effects at different stages of HCC development and progression some effects could evade detection when analysis is performed without differentiation according to tumor stage [2]. However, after grouping patients into early-intermediate (BCLC A-B) and advanced-terminal stage (BCLC C-D), the negative impact of elevated fT$_4$ on survival remained significant in both subgroups. Additionally, non-thyroidal illness syndrome (NTIS), characterized by low serum T$_3$ with normal T$_4$ levels, is associated with HCC and other malignancies [46, 47]. The fact that T$_3$ and fT$_3$ levels were missing in most of our patients represents another potential bias we could not address in our analysis. In light of the stated limitations, this study could not adequately investigate the hypothesis of a dual role of thyroid hormones in HCC [2].

In conclusion, high TSH level was associated with larger tumor size but not with survival when adjusted for known prognostic factors for HCC. Elevation of fT$_4$ resulted in poor survival and remained an independent prognostic factor for OS. These results can be considered as hypothesis-generating paving the path for further work. Prospective studies including clinically hypothyroid patients and subgroup analyses of all tumor stages are needed to further elucidate the role of thyroid hormones in HCC.
Supporting information

S1 Table. Thyroid function.
(DOCX)

S2 Table. Association between TSH and patient, liver, and tumor characteristics in patients with the largest tumor being >5cm.
(DOCX)

S3 Table. Association between free tetraiodothyronine (fT₄) and patient, liver, and tumor characteristics (n = 313).
(DOCX)

S4 Table. Multivariate analysis of prognostic factors.
(DOCX)

Author Contributions

Conceptualization: Wolfgang Sieghart.

Data curation: Matthias Pinter, Lukas Haupt, Florian Hucke, Simona Bota, Theresa Bucsics.

Formal analysis: Matthias Pinter, Lukas Haupt.

Methodology: Wolfgang Sieghart.

Supervision: Michael Trauner, Markus Peck-Radosavljevic, Wolfgang Sieghart.

Writing – original draft: Matthias Pinter, Lukas Haupt.

Writing – review & editing: Matthias Pinter, Lukas Haupt, Florian Hucke, Simona Bota, Theresa Bucsics, Michael Trauner, Markus Peck-Radosavljevic, Wolfgang Sieghart.

References

1. Brown AR, Simmen RC, Simmen FA. The role of thyroid hormone signaling in the prevention of digestive system cancers. Int J Mol Sci. 2013; 14(8):16240–57. Epub 2013/08/09. https://doi.org/10.3390/ijms140816240 PMID: 23924944;

2. Wu SM, Cheng WL, Lin CD, Lin KH. Thyroid hormone actions in liver cancer. Cell Mol Life Sci. 2013; 70(11):1915–36. Epub 2012/09/08. https://doi.org/10.1007/s00018-012-1146-7 PMID: 22955376.

3. Perra A, Plateroti M, Columbano A. T3/TRs axis in hepatocellular carcinoma: new concepts for an old pair. Endocr Relat Cancer. 2016; 23(8):R353–69. Epub 2016/06/30. https://doi.org/10.1530/ERC-16-0152 PMID: 27353037.

4. Hucke F, Sieghart W, Schoniger-Hekele M, Peck-Radosavljevic M, Muller C. Clinical characteristics of patients with hepatocellular carcinoma in Austria—is there a need for a structured screening program? Wien Klin Wochenschr. 2011; 123(17–18):542–51. Epub 2011/07/30. https://doi.org/10.1007/s00508-011-0033-9 PMID: 21800047.

5. Pinter M, Trauner M, Peck-Radosavljevic M, Sieghart W. Cancer and liver cirrhosis: implications on prognosis and management. ESMO Open. 2016; 1:e000042. https://doi.org/10.1136/esmoopen-2016-000042 PMID: 27843598.

6. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65(2):87–108. Epub 2015/02/06. https://doi.org/10.3322/caac.21262 PMID: 25651787.

7. Hulbert AJ. Thyroid hormones and their effects: a new perspective. Biol Rev Camb Philos Soc. 2000; 75(4):519–631. Epub 2000/12/16. PMID: 11117200.

8. Gonzalez-Sancho JM, Garcia V, Bonilla F, Munoz A. Thyroid hormone receptors/THR genes in human cancer. Cancer Lett. 2003; 192(2):121–32. Epub 2003/04/02. PMID: 12668576.

9. Pucci E, Chiovato L, Pinchera A. Thyroid and lipid metabolism. Int J Obes Relat Metab Disord. 2000; 24 Suppl 2:S109–12. Epub 2000/09/21. PMID: 10997623.
10. Sinha RA, Singh BK, Yen PM. Thyroid hormone regulation of hepatic lipid and carbohydrate metabolism. Trends Endocrinol Metab. 2014; 25(10):538–45. Epub 2014/08/17. https://doi.org/10.1016/j.tem.2014.07.001 PMID: 25127738.

11. Frau C, Loi R, Petrelli A, Perra A, Menegon S, Kowalik MA, et al. Local hypothyroidism favors the progression of preneoplastic lesions to hepatocellular carcinoma in rats. Hepatology. 2015; 61(1):249–59. Epub 2014/08/27. https://doi.org/10.1002/hep.27399 PMID: 25156012.

12. Hassan MM, Kaseb A, Li D, Patt YZ, Vauthey JN, Thomas MB, et al. Association between hypothyroidism and hepatocellular carcinoma: a case-control study in the United States. Hepatology. 2009; 49(5):1563–70. Epub 2009/04/29. https://doi.org/10.1002/hep.22793 PMID: 19399911.

13. Chi HC, Chen SL, Liao CJ, Liao CH, Tsai MM, Wu MH, et al. Repression of microRNA-130b by thyroid hormone enhances cell motility. J Hepatol. 2015; 62(6):1328–40. Epub 2015/01/27. https://doi.org/10.1016/j.jhep.2014.12.035 PMID: 25617495.

14. Lin YH, Wu MH, Liao CJ, Huang YH, Chi HC, Wu SM, et al. Association between serum TSH with high body mass differs between smokers and never-smokers. J Clin Endocrinol Metab. 2009; 94(12):5023–7. Epub 2009/10/23. https://doi.org/10.1210/jc.2009-1180 PMID: 19846737.

15. Biondi B. Thyroid and obesity: an intriguing relationship. J Clin Endocrinol Metab. 2010; 95(8):3614–7. Epub 2010/08/06. https://doi.org/10.1210/jc.2010-1245 PMID: 20685890.

16. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012; 56(4):908–43. Epub 2012/03/20. https://doi.org/10.1002/hep.242438.

17. Heimbach J, Kulik LM, Finn R, Sirlin CB, Abecassis M, Roberts LR, et al. Asaasld guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2017. https://doi.org/10.1002/hep.29086 PMID: 28130846.

18. Larsson SC, Wolk A. Overweight, obesity and risk of liver cancer: a meta-analysis of cohort studies. Br J Cancer. 2007; 97(7):1005–8. Epub 2007/09/19. https://doi.org/10.1038/sj.bjc.6603932 PMID: 17700568.

19. Brenta G. Why can insulin resistance be a natural consequence of thyroid dysfunction? J Thyroid Res. 2011; 2011:152850. Epub 2011/09/24. https://doi.org/10.4061/2011/152850 PMID: 21941681.

20. Vyakaranam S, Vanaparthy S, Nori S, Palarapu S, Bhongir AV. Study of Insulin Resistance in Subclinical Hypothyroidism. Int J Health Sci Res. 2014; 4(9):147–53. Epub 2015/01/13. PMID: 25580384.

21. Perros P, McCrimmon RJ, Shaw G, Frier BM. Thyroid hormone receptor associate with tumor invasion in human hepatoma cells. Oncogene. 2011; 30(17):2057–69. Epub 2011/01/11. https://doi.org/10.1038/onc.2010.585 PMID: 21217776.

22. Lin YH, Wu MH, Liao CJ, Huang YH, Chi HC, Wu SM, et al. Thyroid hormone receptors promote metastasis of human hepatoma cells via regulation of TRAIL. Cell Death Differ. 2012; 19(11):1802–14. Epub 2012/05/12. https://doi.org/10.1038/cdd.2012.58 PMID: 22576662.

23. Asvold BO, Bjoro T, Vatten LJ. Association of serum TSH with high body mass differs between smokers and never-smokers. J Clin Endocrinol Metab. 2009; 94(12):5023–7. Epub 2009/10/23. https://doi.org/10.1210/jc.2009-1180 PMID: 19846737.

24. Eshraghian A, Hamidian Jahromi A. Non-alcoholic fatty liver disease and thyroid dysfunction: a systematic review. World J Gastroenterol. 2014; 20(25):8102–9. Epub 2014/07/11. https://doi.org/10.3748/wjg.v20.i25.8102 PMID: 25009382.

25. Pagadala MR, Zein CO, Dasarathy S, Yerian LM, Lopez R, McCullough AJ. Prevalence of hypothyroidism in nonalcoholic fatty liver disease. Dig Dis Sci. 2012; 57(2):528–34. Epub 2011/07/11. https://doi.org/10.1007/s10620-011-2006-2 PMID: 22183820.

26. Antonelli A, Ferri C, Pampana A, Fallahi P, Nesti C, Pasquini M, et al. Thyroid disorders in chronic hepatitis C patients with mild and severe hepatic fibrosis. Ann Hepatol. 2008; 7(1):72–7. Epub 2008/04/01. PMID: 18376370.

27. Rodriguez-Torres M, Rios-Bedoya CF, Ortiz-Lasanta G, Manueax-Cuetara AM, Jimenez-Rivera J. Thyroid dysfunction (TD) among chronic hepatitis C patients with mild and severe hepatic fibrosis. Ann Hepatol. 2008; 7(1):72–7. Epub 2008/04/01. PMID: 18376370.

28. Tarantino G, Citro V, Conca P, Riccio A, Tarantino M, Capone D, et al. What are the implications of the spontaneous spleno-renal shunts in liver cirrhosis? BMC Gastroenterol. 2009; 9:89. https://doi.org/10.1186/1471-230X-9-89 PMID: 19930687.

29. Reddy A, Dash C, Leerapun A, Mettler TA, Stadheim LM, Lazaridis KN, et al. Hypothyroidism: a possible risk factor for liver cancer in patients with no known underlying cause of liver disease. Clin
32. Cristofanilli M, Yamamura Y, Kau SW, Bevers T, Strom S, Patangan M, et al. Thyroid hormone and breast carcinoma. Primary hypothyroidism is associated with a reduced incidence of primary breast carcinoma. Cancer. 2005; 103(6):1128–34. Epub 2005/02/16. https://doi.org/10.1002/cncr.20881 PMID: 15712375.

33. Lehrer S, Diamond EJ, Bajwa AM, Kornreich R, Stone NN, et al. Association between serum triiodothyronine (T3) level and risk of disease recurrence in men with localized prostate cancer. Prostate Cancer Prostatic Dis. 2001; 4(4):232–4. Epub 2002/12/24. https://doi.org/10.1038/sj.pcan.4500542 PMID: 12497024.

34. Hollowell JG, Staehling NW, Flanders WD, Hannon WH, Gunter EW, Spencer CA, et al. Serum TSH, T4, and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab. 2002; 87(2):489–99. Epub 2002/02/16. https://doi.org/10.1210/jcem.87.2.1182980 PMID: 11836274.

35. Sieghart W, Pinter M, Hucke F, Graziadei I, Schoniger-Hekele M, Muller C, et al. Single determination of C-reactive protein at the time of diagnosis predicts long-term outcome of patients with hepatocellular carcinoma. Hepatology. 2013; 57(6):2224–34. Epub 2012/09/11. https://doi.org/10.1002/hep.26057 PMID: 22961713.

36. Wan S, Kuo N, Kryczek I, Zou W, Wellin TH. Myeloid cells in hepatocellular carcinoma. Hepatology. 2015; 62(4):1304–12. Epub 2015/04/29. https://doi.org/10.1002/hep.27867 PMID: 25914264.

37. Maeda S, Kamata H, Luo JL, Leffert H, Karin M. IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell. 2005; 121(7):977–90. Epub 2005/07/02. https://doi.org/10.1016/j.cell.2005.04.014 PMID: 15989949.

38. Rossi JF, Lu ZY, Jourdan M, Klein B. Interleukin-6 as a therapeutic target. Clin Cancer Res. 2015; 21(6):1248–57. Epub 2015/01/16. https://doi.org/10.1158/1078-0432.CCR-14-2291 PMID: 25589616.

39. Chen RN, Huang YH, Lin YC, Yeh CT, Liang Y, Chen SL, et al. Thyroid hormone promotes cell invasion through activation of furin expression in human hepatoma cell lines. Endocrinology. 2008; 149(8):3817–31. Epub 2008/05/10. https://doi.org/10.1210/en.2007-0989 PMID: 18467449.

40. Lin KH, Shieh HY, Hsu HC. Negative regulation of the antimetastatic gene Nm23-H1 by thyroid hormone receptors. Endocrinology. 2000; 141(7):2540–7. Epub 2000/06/30. https://doi.org/10.1210/endo.141.7.7570 PMID: 10875256.

41. Riesenbeck LM, Bierer S, Hoffmeister I, Kopke T, Papavassilis P, Hertle L, et al. Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients treated with sorafenib or sunitinib. World J Urol. 2011; 29(6):807–13. Epub 2010/12/15. https://doi.org/10.1007/s00345-010-0627-2 PMID: 21159287.

42. Ahmadieh H, Salti I. Tyrosine kinase inhibitors induced thyroid dysfunction: a review of its incidence, pathophysiology, clinical relevance, and treatment. Biomed Res Int. 2013; 2013:725410. Epub 2013/11/28. https://doi.org/10.1155/2013/725410 PMID: 24282820.

43. Schmidinger M, Vogl UM, Bojc M, Lammm W, Heinz H, Haitel A, et al. Hypothyroidism in patients with renal cell carcinoma: blessing or curse? Cancer. 2011; 117(3):534–44. Epub 2010/09/17. https://doi.org/10.1002/cncr.25422 PMID: 20845482.

44. Ledda-Columbano GM, Perra A, Loi R, Shinozuka H, Columbano A. Cell proliferation induced by triiodothyronine in rat liver is associated with nodule regression and reduction of hepatocellular carcinomas. Cancer Res. 2000; 60(3):803–9. Epub 2000/02/17. PMID: 10676643.

45. Perra A, Kowalk MA, Pibiri M, Ledda-Columbano GM, Columbano A. Thyroid hormone receptor ligands induce regression of rat preneoplastic liver lesions causing their reversion to a differentiated phenotype. Hepatology. 2009; 49(4):1287–96. Epub 2008/12/31. https://doi.org/10.1002/hep.22750 PMID: 19115221.

46. Srivastava J, Robertson CL, Greder R, Siddiq A, Rajasekaran D, Akiel MA, et al. Astrocyte Elevated Gene-1 (AEG-1) Contributes to Non-thyroidal Illness Syndrome (NTIS) Associated with Hepatocellular Carcinoma (HCC). J Biol Chem. 2015; 290(25):15549–58. Epub 2015/05/07. https://doi.org/10.1074/jbc.M115.649707 PMID: 25944909.

47. Warner MH, Beckett GJ. Mechanisms behind the non-thyroidal illness syndrome: an update. J Endocrinol. 2010; 205(1):1–13. Epub 2009/12/18. https://doi.org/10.1677/JOE-09-0412 PMID: 20016054.